Market Overview

UPDATE: Goldman Sachs Lowers PT to $22 on Impax Laboratories on Competitive Risks

Share:
Related IPXL
Benzinga's Top Upgrades, Downgrades For July 18, 2017
Turing Board Could Appoint Founder Martin Shkreli As CEO Or Chairman, But He Has No Interest

Goldman Sachs reiterated its Sell rating on Impax Laboratories (NASDAQ: IPXL) and reduced its price target from $24 to $22.

Goldman Sachs commented, "Third quarter revenues and disappointing fourth quarter guidance both suggest that competitive pressures in the generics segment are greater than we had anticipated. Weak Adderall XR sales as well as the further declines implied by guidance suggest that Actavis competition has driven greater-than-anticipated pricing pressure. Fourth quarter guidance was further pressured by earlier-than-expected fenofibrate competition."

Impax Laboratories closed at $24.34 on Friday.

Latest Ratings for IPXL

DateFirmActionFromTo
Jul 2017PiperJaffrayUpgradesUnderweightNeutral
Jul 2017Deutsche BankMaintainsBuy
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for IPXL
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (IPXL)

View Comments and Join the Discussion!